The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Pennsylvania will receive $1.28 million as part of a $202 million national settlement with Gilead Sciences Inc., after the company was accused of orchestrating an illegal ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

Pennsylvania looks to be getting millions from a biopharma company for violating anti-kickback laws. Gilead Sciences, Inc.

A company was ordered to pay hundreds of thousands of dollars to D.C. to settle claims that it engaged in an illegal kickback scheme.

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...